Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Voyager TherapeuticsFRA:VT6 -0.71%43 3-Year Book Growth Rate is 29.50% as of Jun. 2026, which is 620% above its 10-year median of 4.10. GuruFocus rates FRA:VT6 with a GF Score™ of 43/100 and a GF Value™ of €1.11 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,123 Biotechnology companies, Voyager Therapeutics ranks better than 88.25% on this metric.
During the past 12 months, Voyager Therapeutics's average Book Value per Share Growth Rate was -42.80% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 29.50% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 7.40% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -2.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Voyager Therapeutics was 29.80% per year. The lowest was -40.40% per year. And the median was 4.10% per year.
Voyager Therapeutics (FRA:VT6) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Voyager Therapeutics 3-Year Book Growth Rate Related Terms
FRA:VT6 vs CHRS, KROS, DTIL: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Voyager Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's 3-Year Book Growth Rate falls into.
Voyager Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 29.50% mean?
Voyager Therapeutics (FRA:VT6) has a 3-Year Book Growth Rate of 29.50% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Voyager Therapeutics and its competitors. This is 620% above median its historical median of 4.10. According to the industry distribution chart, Voyager Therapeutics ranks #132 out of 1123 companies in the Biotechnology industry, placing it in the top 11.8%.
Is Voyager Therapeutics' 3-Year Book Growth Rate too high?
Voyager Therapeutics' current 3-Year Book Growth Rate of 29.50% is 620% above median its 10-year median of 4.10. Based on the distribution chart, Voyager Therapeutics ranks #132 out of 1123 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Voyager Therapeutics has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' 3-Year Book Growth Rate compare to CHRS and KROS?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #132 out of 1123 companies for 3-Year Book Growth Rate. This places Voyager Therapeutics in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Voyager Therapeutics and its competitors. Voyager Therapeutics's current 3-Year Book Growth Rate is 29.50%, which is 620% above median its own 10-year median of 4.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.11, compared to a current price of €2.53 — trading 127.9% above its estimated fair value. The current 3-Year Book Growth Rate is 29.50%, which is 620% above median its 10-year median of 4.10. Voyager Therapeutics' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current 3-Year Book Growth Rate is 29.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €2.53 is trading 127.9% above its estimated GF Value™ of €1.11.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
3-Year Book Growth Rate: 29.50% (620% above median its 10-year median of 4.10)
GF Value™: €1.11 vs. price of €2.53 (127.9% above fair value)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
43GF Score
Get the complete analysis for FRA:VT6
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 
